Test Price
2,800 AED✅ Home Collection Available
QDPR Gene Hyperphenylalaninemia, BH4-Deficient, Type C Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Executive Summary: This advanced molecular genetic test provides definitive diagnosis of BH4-deficient hyperphenylalaninemia type C caused by dihydropteridine reductase deficiency. Using targeted next-generation sequencing of the QDPR gene, the assay achieves 99.9% diagnostic sensitivity for detecting disease-causing variants across all coding exons and splice junctions. Results are essential for differentiating BH4-responsive from non-responsive hyperphenylalaninemia and for guiding lifelong metabolic therapy with tetrahydrobiopterin and neurotransmitter precursors.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The QDPR Genetic Test employs targeted next-generation sequencing to analyze the complete coding region and intron-exon boundaries of the QDPR gene (GRCh38 reference assembly). This approach detects missense, nonsense, frameshift, splice-site, and copy-number variants that impair dihydropteridine reductase activity, leading to accumulation of phenylalanine and depletion of tetrahydrobiopterin. Definitive molecular diagnosis enables precision therapy with sapropterin dihydrochloride, levodopa, and 5-hydroxytryptophan while avoiding irreversible neurological damage.
| Feature | Our QDPR NGS Test | Closest Alternative (Biochemical Screening) |
|---|---|---|
| Precision | 99.9% Diagnostic Sensitivity; single-nucleotide variant detection across all coding regions | Moderate sensitivity; may miss mild variants or atypical presentations |
| Method | Targeted Next Generation Sequencing (NGS) of QDPR gene (GRCh38) | Enzymatic assay of dihydropteridine reductase activity in blood spots / timed urine pterin analysis |
| Speed | Results delivered in 3-4 Weeks | Results typically within 1-2 weeks, but often require confirmatory genetic testing |
Physician Insight & Safety Protocols
“In my practice, confirming a biallelic pathogenic QDPR variant fundamentally alters the clinical trajectory — it justifies lifelong tetrahydrobiopterin replacement and neurotransmitter precursor therapy while ruling out classical phenylketonuria. Post-test genetic counselling must address autosomal recessive recurrence risk, carrier testing for siblings, and prenatal diagnostic options for future pregnancies. Metabolic emergency preparedness remains paramount even after molecular confirmation.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Medication Continuity & Clinical Oversight
Patients currently prescribed sapropterin, levodopa/carbidopa, or 5-hydroxytryptophan must not alter or discontinue these medications without direct supervision from their managing metabolic physician. Abrupt cessation can precipitate acute neurotransmitter depletion manifesting as dystonia, oculogyric crisis, or life-threatening autonomic instability. All therapy adjustments should be guided by molecular results in conjunction with plasma phenylalanine, CSF neurotransmitter metabolite panels, and serial clinical assessments.
Exclusion Criteria & Emergency Red Flags
- Neonates with positive newborn screening must receive immediate clinical evaluation and confirmatory biochemistry; DNA testing is complementary, not a first-line emergency.
- Patients experiencing acute dystonia, seizures, or severe movement disorders require urgent metabolic crisis management — do not postpone care while awaiting genetic results.
- Test is not suitable as a stand-alone screening without concurrent plasma amino acid and CSF neurotransmitter analysis if clinically indicated.
- If the patient is a minor, consent and counselling must comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Decree-Law No. 4 of 2016 on Medical Liability regarding informed consent for genetic testing.
Patient FAQ & Clinical Guidance
1. What exactly does the QDPR Gene NGS test detect?
A: The QDPR Genetic Test accurately detects disease-causing mutations in the QDPR gene responsible for BH4-deficient hyperphenylalaninemia type C. It sequences all coding exons and splice junctions, identifying missense, nonsense, frameshift, and splice-site variants that impair dihydropteridine reductase activity. Results directly guide treatment with tetrahydrobiopterin and neurotransmitter precursors.
2. How is the test performed and what is the turnaround time?
A: A single peripheral whole blood draw, dried blood spot (FTA card), or extracted DNA is analyzed via targeted NGS. Results are returned within 3-4 weeks. Our home collection team follows ISO-certified cold-chain protocols, and VIP mobile phlebotomy is available daily from 8 AM to 11 PM, seven days a week.
3. Is the test covered by medical insurance in the UAE?
A: Many UAE insurers cover genetic testing for metabolic disorders when accompanied by a physician referral. Our team provides direct billing verification via WhatsApp at +971 54 548 8731. We confirm pre-authorization, co-pay, and eligibility under your plan immediately after receiving your referral form.
UAE Regulatory & Data Privacy Adherence
This clinical genetic testing service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient genomic data is encrypted, access-restricted, and processed exclusively within DHA-licensed facilities. All laboratory procedures are ISO 9001:2015 accredited (Cert: INT/EGQ/2509DA/3139). Informed consent for genetic analysis adheres to Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring patients and families receive pre- and post-test counselling regarding inheritance patterns, carrier risks, and data confidentiality rights.
Clinical & Logistical Metadata
| Test Name | QDPR Gene Hyperphenylalaninemia, BH4-Deficient, Type C Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3-4 Weeks (21-28 Business Days) |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA), Dried Blood Spot (FTA Card), or Extracted DNA |
| Methodology Used | Targeted Next Generation Sequencing (NGS) – QDPR gene, full coding region & splice junctions (GRCh38) |
| ICD-10-CM Code | E70.1 (Other hyperphenylalaninemia) |
| LOINC Code | 55233-1 (Gene mutations identified in Blood or Tissue by Sequencing) |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians